Diffuse Large B-Cell Lymphoma (DLBCL) - Global Clinical Trials Review, 2026 | CAR-T and Phase III Pipelines Fuel Investment and Partnership Opportunities

October 22, 2026

Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage.

Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2026" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive overview of the global Diffuse Large B-Cell Lymphoma clinical trials landscape in 2026. It presents top line data on trial activity, including the number of studies and average patient enrollment across leading countries. The analysis enables pharmaceutical companies, biotechnology organizations, investors, clinical research organizations and other industry stakeholders to assess current research activity and identify emerging opportunities within the Diffuse Large B-Cell Lymphoma therapeutics market.

Coverage includes clinical trials segmented by region, country, phase, trial status, end point status and sponsor type. Country-level analysis incorporates G7 and E7 markets, supporting comparisons between established and emerging clinical research locations. The report also identifies prominent drugs involved in in-progress trials based on the number of ongoing studies, offering insight into active development programs and the competitive clinical pipeline.

The findings are generated using the analyst's proprietary Pharma - Clinical trials database. Information is collated from more than 80 clinical trial registries, conferences, peer-reviewed journals, company announcements, news sources and other industry channels worldwide. The database is updated periodically through a dynamic process to maintain the relevance and accuracy of the available clinical trial information.

Report Scope

Provides a current snapshot of the global Diffuse Large B-Cell Lymphoma clinical trials landscape.
Analyzes clinical trial activity by region, G7 and E7 country, trial phase, trial status, sponsor type and end point status.
Reviews trial numbers and average enrollment across major clinical research markets.
Examines enrollment trends recorded during the past five years to support market and pipeline assessment.
Profiles leading companies involved in Diffuse Large B-Cell Lymphoma clinical development.
Lists relevant studies associated with each profiled company, including trial title, phase and status.
Identifies prominent drugs in in-progress clinical trials according to the number of ongoing studies.
Assesses unaccomplished trials categorized as terminated, suspended or withdrawn and includes the reported reasons for discontinuation.
Summarizes relevant Diffuse Large B-Cell Lymphoma clinical trial news published during the past three months.

Business Value

The report supports evidence-based decision-making and the development of effective competitive strategies. Its structured analysis can assist organizations in evaluating investment priorities, benchmarking clinical development activity and identifying markets with favorable trial conditions. By comparing study volume, enrollment patterns and sponsor participation, stakeholders can improve strategic planning across global, regional and country-level operations.

Supports the formulation of business and investment strategies related to Diffuse Large B-Cell Lymphoma drug development.
Helps identify prominent locations for conducting clinical trials, with the potential to improve timelines and manage costs.
Highlights business opportunities across the global clinical trials market through analysis of research activity and development trends.
Enables comparison of clinical trial counts and patient enrollment trends across key countries.
Provides insight into trial outcomes through comparative analysis of completed studies and trials that were terminated, suspended or withdrawn.
Facilitates assessment of the Diffuse Large B-Cell Lymphoma pipeline at global, regional and country levels.
Supports competitive intelligence by identifying leading sponsors, active companies and prominent investigational drugs.
Assists clinical development teams in evaluating trial phases, statuses and end point trends within the indication.

The report is designed to strengthen clinical trial planning, market assessment and competitive positioning in the global Diffuse Large B-Cell Lymphoma sector. Certain sections may be removed or altered depending on the availability and relevance of data for the indicated disease.

Key Topics Covered:

Report Guidance
The analyst Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma
Mar 22, 2026: HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in China
Mar 10, 2026: Imugene Reports 100% & 80% Overall Response Rate in Subset Indications in azer-cel Phase 1b study
Mar 06, 2026: Elicera Therapeutics Reports CMR and Well Tolerated Treatment in First Two Patients of Cohort 3 in Carma Study, Bringing CMR to 6 Out of 8 Patients
Mar 04, 2026: Citius Oncology Announces Topline Phase 1 Data from Study of E7777 Dosing Prior to Commercial CAR-T Therapy in High-Risk DLBCL
Feb 13, 2026: Lyell doses first patient in Phase III trial for LBCL
Feb 05, 2026: Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
Jan 29, 2026: MT-2111 Achieved Primary Endpoint in Phase 2 part of Japanese Phase 1/2 study for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jan 19, 2026: Genmab reports top line results in Phase III DLBCL trial
Jan 06, 2026: Incyte reports positive data from tafasitamab Phase III trial for DLBCL
Clinical Trial Profile Snapshots
Abbreviations
Definitions
Research Methodology
Secondary Research
About the Analyst
Contact the Publisher
Disclaimer
Source

List of Tables [23]

List of Figures [24]

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/e5c5kp

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

About us	Network	Partners
Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos	Analist.nlLinksISIN Glossary	MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x